Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC 007 in Healthy Young and Elderly Subjects
NCT02955420Phase 1Completed
- Sponsor
- Berlin Cures
- Start
- Aug 2016
- Primary completion
- Apr 2018
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic heart failure (CHF), pulmonary hypertension (PH) and myalgic encephalomyelitis chronic fatigue syndrome (ME/CFS) comparing BC 007 with Placebo (2 arms). Primary endpoints: Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment at 24 hours and Conversion rate from positive GPCR AAB to negative immune status at 24 hours. Started Aug 2016; status: completed.
02
Drugs
rovunaptabin
03
Conditions
chronic heart failure (CHF)pulmonary hypertension (PH)myalgic encephalomyelitis chronic fatigue syndrome (ME/CFS)
Beyond the preview
Go deeper on NCT02955420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02955420.